Curcumin and gemcitabine in patients with advanced pancreatic cancer

Nutrition and Cancer

Volumn 62, Issue 8, 2010, Pages 1137-1141

  Epelbaum, Ron ^a,b   Schaffer, Moshe ^a   Vizel, Bella ^a   Badmaev, Vladimir ^c   Bar Sela, Gil ^a,b  

^a Rambam Health Care Campus ^*  (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c SABINSA CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CURCUMIN; GEMCITABINE;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG MEGADOSE; FEASIBILITY STUDY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; MALE; METASTASIS; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PHASE 2 CLINICAL TRIAL; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADENOCARCINOMA; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CURCUMIN; DEOXYCYTIDINE; DISEASE PROGRESSION; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PANCREATIC NEOPLASMS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

EID: 78249286547     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1080/01635581.2010.513802     Document Type: Article

References (31)

1. Yeo CJ, Yeo TP, Hruban RH, Kern SE, Iacobuzio-Donohue CA, et al.: Cancer of the pancreas. In: Cancer: Principles and Practice of Oncology, DeVita VT, Hellman S and Rosenberg SA (eds.), 7th ed. Philadelphia: Lippincott Williams & Wilkins, 2005, pp. 139-161.
2. Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, et al.: Improvement in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15, 2403-2423, 1997.
3. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR et al.: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Instituteof Canada Clinical Trials Group. J Clin Oncol 25, 1960-1966, 2007.
4. Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J, et al.: Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 25, 212-217, 2007.
5. Sultana A, Tudur Smith C, Cunningham D, Starling N, Neoptolemos J, et al.: Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 25, 2607-2615, 2007.
6. Aggarwall B, Kumar A, and Bharti AC: Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 23, 363-398, 2003.
7. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, et al.: Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 21, 2895-2900, 2001.
8. Sharma RA, McLelland HR, Hill KA, Ireson CR, Euden SA, et al.: Pharmacodynamic and pharmacokinetic study of oral curcuma extract in patients with colorectal cancer. Clin Cancer Res 7, 1894-1900, 2001.
9. Sharma RA, Euden SA, Platton SH, Cooke DN, Shafayat A, et al.: Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 10, 6847-6854, 2004.
10. Dhillon N, Aggarwal BB, Newman RA, Wolf RA, Kunnumakkara AB, et al.: Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 14, 4491-4499, 2008.
11. Sen S, Sharma H, and Singh N: Curcumin enhances vinorelbine mediated apoptosis in NSCLC cells by the mitochondrial pathway. Biochem Biophys Res Commun 331, 1245-1252, 2005.
12. Patel BB, Sengupta R, Qazi S, Vachhani H, Yu Y, et al.: Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R. Int J Cancer 122, 267-273, 2008.
13. Aggarwal BB, Shishodia S, Takada Y, Banerjee S, Newman RA, et al.: Curcumin suppresses the paclitaxol-induced nuclear factor-kappa B pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res 11, 7490-7498, 2005.
14. Lev-Ari S, Vexler A, Starr A, Ashkenazy-Voghera M, Greif J, et al.: Curcumin augments gemcitabine cytotoxic effect on pancreatic adenocarcinoma cell lines. Cancer Inves 25, 411-418, 2007.
15. Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Geloveni J, et al.: Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferative, angiogenesis and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res 67, 3853-3861, 2007.
16. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al.: New guidelines to evaluate the response to treatment in solid tumors. J Nat Cancer Inst 92, 205-216, 2000. (Pubitemid 30099779)
17. National Cancer Institute: Common Terminology Criteria for Adverse Events, v. 3.0, 2003.
18. Storniolo AM, Enas NH, Brown CA, Voi M, Rothenberg ML, et al.: An investigational new drug treatment program for patients with gemcitabine. Cancer 85, 1261-1268, 1999.
19. Kuttan G, Kumar KB, Guruvayoorappan C, and Kuttan R: Antitumor, antiinvasion and antimetastatic effects of curcumin. Adv Exp Med Biol 595, 1173-1184, 2007.
20. Anand P, Sundaram C, Jhurani S, Kunnumakkara AB, and Aggarwal BB: Curcumin and cancer: an "old-age" disease with an "old-age" solution. Cancer Lett 267, 133-164, 2008.
21. Hatcer H, Planalp R, Cho J, Torti FM, and Torti SV: Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci 65, 1631-1652, 2008.
22. Kuttan R, Sudheeran PC, and Josph CD: Tumeric and curcumin as topical agent in cancer therapy. Tumori 73, 29-31, 1987.
23. Lao CD, Ruffin MT, Normolle D, Health DD, Murray SI, et al.: Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 6, 10-13, 2006.
24. Mahattanadul S, Reanmongkol W, Yano S, Panichayuupakaranant P, Phdoongsombut N, et al.: Preventive and curative effects of curcumin on the development of gastric inflammatory diseases in rats. J Nat Med 60, 191-197, 2006.
25. Prucksunand C, Indrasukhsri B, Leethochawalit M, and Hungspreugs K: Phase II clinical trial on effect of the long turmeric (Curcuma Longa Linn) on healing of peptic ulcer. Southeast Asian J Trop Med Public Health 23, 208-215, 2001.
26. Gupta B, Kulshrestha VK, Srivastava RK, and Prasad DN. Mechanisms of curcumin induced gastric ulcer in rat. Indian J Med Res 71, 806-814, 1980.
27. Kelloff GJ, Crowell JA, Hawk ET, Steele VE, Lubet RA, et al.: Strategy and planning for chemopreventive drug development: clinical development plans II. J Cell Biochem Suppl 26, 54-71, 1996.
28. Van Dau N, Ngoc Ham N, Huy Khac D, Thi Lam N, Tong Son P, et al.: The effect of traditional drug tumeric (Curcuma Longa) and placebo on healing of duodenal ulcer. Phytomedicine 5, 29-34, 1998.
29. Garcea G, Berry DP, Jones D J L, Singh R, Dennison AR, et al.: Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol Biomarkers Prev 14, 120-125, 2005.
30. Bisht S and Maitra A: systemic delivery of curcumin: 21st century solutions for an ancient conundrum. Curr Drug Discov Technol 6, 192-199, 2009.
31. Li L, Braiteh FS, and Kurzrock R: Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling and angiogenesis. Cancer 104, 1322-1331, 2005.